Ginkgo Bioworks Narrows Q3 Loss and Signs Novo Lab Deal
Ginkgo Bioworks announced on November 5, 2026 that its third-quarter GAAP net loss from continuing operations narrowed to $41 million from $73 million a year earlier, alongside its first autonomous-lab sale to a top-tier pharmaceutical company, Novo. The year-over-year improvement came from lower spending, not higher revenue. Revenue was $28 million for the quarter ended September 30, 2026, down 6% from $29 million in the comparable prior-year period, although it rose from $20 million in the…